Business
Bausch Health Announces Second Quarter 2025 Results
Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Org...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Bausch Health Announces Second Quarter 2025 ResultsSecond Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health Companies of $148 million and GAAP Net Income of $128 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP)1 of $842 million, up 6% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB SECOND QUARTER 2025 RESULTSDelivered ninth consecutive quarter of year-over-year Revenue and Adjusted EBITDA (non-GAAP)1 growth, with 5% both Reported and Organic (non-GAAP)1 Revenue growth, and 10% Adjusted EBITDA (non-GAAP)1 growthAnnounced upcoming repayment of approximately $900 million dollars of debt using cash on hand after quarter-endEntered into an agreement to acquire DURECT Corporation in July, which if all closing conditions are satisfied and the acquisition closes, will enable Bausch Health to use its hepatology expertise to seek to gain approvals and commercialize DURECT's main treatment for alcohol-induced hepatitisReaffirming full-year 2025 Revenue, Adjusted EBITDA (non-GAAP)1, and Adjusted Cash Flow from Operations (non-GAAP)1 guidance LAVAL, QC / ACCESS Newswire / July 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (\"Bausch Health\" or the \"Company\" or \"we\" or \"our\") today announced its second quarter 2025 financial results and other key updates from the quarter.\"In the second quarter, we achieved our ninth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb. This consistent performance highlights our operational excellence and the strength of our diverse portfolio across therapeutic areas and geographies. As we look toward the second half of 2025, we remain focused on executing against our strategic priorities to drive continued growth and unlock long-term value for our shareholders,\" said Thomas J. Appio, Chief Executive Officer, Bausch Health.Second Quarter 2025 Revenue PerformanceTotal consolidated reported revenues were $2.53 billion for the second quarter of 2025, compared with $2.40 billion in the second quarter of 2024, an increase of $127 million, or 5%. Excluding the impact of foreign exchange of $21 million, acquisitions of $6 mil...